Many studies have demonstrated that phenylbutyrate, a drug used in the treatment of urea acid cycle disorders, and VPA increase SMN2 transcripts and full-length SMN protein in different types of cells from patients and in animal models of SMA [13-16]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.